- Home
-
Press releases
-
Media academy
- Lung Cancer
- Breast Cancer
- Ovarian Cancer
- Head & Neck Cancer
- Targeted Therapy
Marianne Nicolson
Consultant Medical Oncologist, Aberdeen Royal Infirmary, Aberdeen, Scotland
At the ASCO meeting in 2009, there were data presented for ovarian carcinoma, where patients were randomised to receive either BIBF 1120* or placebo. And at 36 weeks, there was a difference in terms of the outcomes in that in favour of the drug, 14% of patients had not progressed compared with 5% of the placebo arm. So, clearly that was a statistically significant difference in favour of maintenance BIBF 1120* compared with placebo. That’s the kind of study that may well change practice. It’s quite exciting.
Source for healthcare professionals: www.inoncology.com
* Nintedanib (BIBF 1120), afatinib (BIBW 2992) and volasertib (BI 6727) are investigational compounds. Their safety and efficacy have not yet been fully established.
